atezolizumab
roche
['goblet']
oncolytics biotech | presents updated #clinicaldata at sitc annual meeting showing a 69% objective response rate and confirmed complete response in goblet study's #pancreaticcancer cohort | #sitc22 #pancreaticcancerresearch #biotech 